Sanofi gets European Commission nod for hemolytic anemia drug Enjaymo Ruchika Sharma19 Nov 2022 12:30 PM ISTEnjaymo is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part...
Sanofi gets EMA Committee recommendation for approval of Enjaymo for hemolytic anemia in adult patients with cold agglutinin disease Ruchika Sharma18 Sept 2022 10:45 AM ISTParis: Sanofi has recently announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted...
Sutimlimab increases Hb levels, prevents hemolysis in cold agglutinin disease: NEJM Medha Baranwal8 April 2021 7:45 AM ISTDelhi: Selective upstream inhibition of activity in the classic complement pathway rapidly reduced fatigue, increased hemoglobin levels, and halted...
Sanofi gets USFDA priority review for sutimlimab for Hemolysis Ruchika Sharma17 May 2020 11:00 AM ISTParis: The U.S. Food and Drug Administration (FDA) has granted priority review of Sanofi's Biologics License Application (BLA) for sutimlimab for the...
